ATC
Altech Batteries Ltd
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
14
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Altech Batteries Ltd. is a specialty battery technology company, which engages in commercializing a 100 MWh solid state sodium alumina battery production facility and developing battery materials for a Lithium-ion battery. The company is headquartered in Subiaco, Western Australia and currently employs 11 full-time employees. The company went IPO on 2010-01-27. The firm is engaged in the development of a 10,000 tons per annum (tpa) silicon graphite anode plant in the state of Saxony, Germany, using its alumina coating technology. The battery technology uses table salt and is lithium-free; cobalt-free; graphite-free; and copper-free. The Company’s principal activities include the establishment of a research and development laboratory in Perth, Western Australia as a facility for the further development of its methods for the alumina coating of graphite and silicon particles, typical of those used within the anode of a lithium-ion battery. The company has a joint venture agreement to commercialize the CERENERGY Sodium Alumina Solid State (SAS) Battery. The firm is also focused on construction and operation of a 4,500 tpa high purity alumina (HPA) processing plant at Johor, Malaysia.
📈 Performance
Price History
-18.24%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
0%
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.10
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in ATC
14
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in ATC
501 days
ATC investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
59%
Less than 50k
29%
👶 Age of investors
18 - 25
26 - 34
50%
35 - 90
50%
🙋 Legal gender of investors
Female
36%
Male
64%
Pearlers who invest in ATC also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
📊 Share price
$43.11 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
📊 Share price
$12.45 AUD
NULL GLOBAL
NULL SMART BETA
NULL ETHICAL
NULL EX AUSTRALIA
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
Want more shares? Try these...
ATEC.AX was created on 2020-03-04 by BetaShares. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 175.82m in AUM and 38 holdings. The investment objective of the Fund is to provide an investment return that aims to track the performance of the S&P/ASX All Technology Index (the Index), before taking into account fees and expenses.
📊 Share price
$18.71 AUD
Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company is headquartered in Melbourne, Victoria and currently employs 12 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The Company’s lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson’s disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
📊 Share price
